Endocrine Abstracts

Pituitary ACTH-secreting tumour presents with variety of clinical features: normal cortisol secretion and ACTH-immunopositive staining and mild hypercortisolism without typical features of Cushing’s disease. We present a 53-year-old male with history of hypertension. First visit (2005): visual loss, bitemporal hemianopsia in campimetry and in MRI pituitary adenoma (2.5 cm) invading cavernous sinus and suprasellar cister. Hormonal study supported panhypopituitarism. After ...

Introduction: Oncocytomas are tumours composed by oncocytes, cells with granular and eosinophilic cytoplasm filled with mitochondria. It is a neoplasm that can arise in several organs (more commonly described in the kidney, salivary gland and thyroid). Oncocytoma arising in the adrenal gland is a rare finding. Most of them are benign and non-functioning and are detected incidentally. However, functional adrenal oncocytomas presenting as Cushing’s syndrome and phaeochromoc...

Introduction: Cushing’s syndrome (CS) due to macronodular adrenal hyperplasia ACTH-independent (MAHAI) is rare. Regulation of cortisol secretion by G-protein-coupled receptors (GPCRs) aberrantly expressed is frequently found in MAHAI. Various aberrant receptors have been reported, mostly: GIP, vasopressin, beta-adrenergic, LH/hCG and serotonin.Case report: 61 years old woman. Medical history: type 2 diabetes, hypertension, obesity, dyslipidaemia and...

Objective: To evaluate the efficacy of liraglutide, a new glucagon-like peptide 1 analogue, on glycaemic control, body weight, blood pressure and lipid profile in obese patients with type 2 diabetes mellitus (T2DM).Material and methods: Patients attending a tertiary Endocrinology Unit who were prescribed liraglutide (January 2013–December 2013) and assessed both at baseline and first post-initiation visit were included in the analysis. The primary e...

Introduction: Obesity is defined as a chronic disease by AACE/ACE. Includes presence/severity of complications. VLCD diets induce relevant weight loss by improving these complications. PA is a bioelectric measure of the cell mass and it is marker a global prognostic factor of cellular functionalism.Methods: Case-control retrospective study of severe obesity in a weight loss program comparing intensive intervention (41 cases, VLCD 800 kcal/d, 1g protein/k...

Background and aim: Obesity (Ob) is tightly associated with metabolic diseases such as type 2 diabetes (DT2) andinsulin resistance (IR). Furthermore, obesity has been identified as one of the primary causes of mood disorders (MDs) including depression. Several studies have demonstrated the link between Ob, adiposity, neuroinflammation and MDs. The Brain-Derived Neurotrophic Factor (BDNF) and its regulator, the non-coding RNA BDNF antisense RNA (BDNFas), play an import...

Introduction and objectives: The treatment with monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) is a new group of drugs that allows us to reach the therapeutic targets of low density cholesterol (LDL-c) in patients intolerant to statins or those who despite treatment with maximum doses of them do not obtain a proper lipid control.Material and methods: We performed a descriptive observational study. We include all ...

Introduction: New long-acting insulin analogues (insulin degludec –ID- and insulin glargine 300 U/ml –IG300-) have proved, in clinical trials, that improve metabolic control with lower hypoglycemia rate in T2D.Objective: To assess characteristics of T2D patients who were given ID and IG300 and to evaluate their effect on metabolic control, weight and insulin dose.Material and methods: We studied T2D patients whose treatme...

Aim: To assess a perioperative glucocorticoid protocol in transsphenoidal surgery (TSS)and the performance of early post-TSS 08:00 cortisol measurement to detect/exclude secondary adrenal insufficiency.Methods: We selected patients undergoing TSS.In patients with no cushing disease, we checked cortisol/Synachten presurgery, measured 3° postoperative 0800 a.m. cortisol(after 24 h without corticoids) and cortisol/Synachten 3-6 months post-surgery. We ...

IntroductionSodium-glucose cotransporter-2 inhibitors (SGLT2i) are a new class of oral antidiabetic drugs used for the treatment of type 2 diabetes mellitus. Recently, the SGLT2i dapagliflozin was approved for use in type 1 diabetes (T1DM) as an add-on to insulin therapy.Material and methodsWe conducted a retrospective observational study which included demographic and clinical-analytical data from 16 patient...